Related references
Note: Only part of the references are listed.A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models
Wei Wei et al.
CLINICAL CANCER RESEARCH (2020)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen et al.
BLOOD (2015)
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
Youn H. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
Madeleine Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Steven M. Horwitz et al.
BLOOD (2014)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma
Sarah Park et al.
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study
Jehan Dupuis et al.
BLOOD (2006)
Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-κB p52, which is associated with hyperphosphorylated Bcl-3
M Nishikori et al.
CANCER SCIENCE (2005)
Share Paper
